Invivyd’s PEMGARDA™ Shows Consistent Neutralization Activity Against Dominant SARS-CoV-2 Variant LP.8.1
Waltham, MA – Invivyd, Inc., a leading biotechnology company, recently announced that its COVID-19 monoclonal antibody (mAb), PEMGARDA™ (pemivibart), continues to demonstrate clinically meaningful in vitro neutralization activity against the currently dominant SARS-CoV-2 variant, LP.8.1. This data is encouraging, as it indicates that PEMGARDA maintains its efficacy against the latest variant, providing hope for those who are immunocompromised and at a higher risk of severe COVID-19.
Background
Since the onset of the COVID-19 pandemic, various SARS-CoV-2 variants have emerged, each with the potential to evade the immune response elicited by vaccines and therapeutics. However, Invivyd’s PEMGARDA and next-generation mAb candidate, VYD2311, have proven to be resilient against these variants. The epitope these mAbs target remains structurally intact, ensuring their continued effectiveness.
Clinically Meaningful Neutralization Data
The latest data from Invivyd’s study reveals that PEMGARDA’s neutralization activity against LP.8.1 is not significantly different from its neutralization activity against earlier SARS-CoV-2 variants. This consistency is crucial, as it reinforces the reliability of PEMGARDA as a prophylactic measure for immunocompromised individuals.
Next-Generation mAb, VYD2311, Shows Similar Results
In parallel, Invivyd’s next-generation mAb candidate, VYD2311, also showed no meaningful change in neutralization activity against LP.8.1. This finding further strengthens the potential of VYD2311 as a future COVID-19 therapeutic option.
Implications for Individuals
For individuals who are immunocompromised, this data is reassuring. PEMGARDA’s continued efficacy against the dominant SARS-CoV-2 variant, LP.8.1, means that they can continue to rely on this treatment as a protective measure against COVID-19. However, it is essential to remember that no treatment is a substitute for vaccination. Vaccination remains the most effective way to prevent COVID-19 infection and its associated complications.
Global Implications
The consistent neutralization activity of PEMGARDA against the dominant SARS-CoV-2 variant, LP.8.1, is a significant step forward in the fight against COVID-19. It underscores the importance of investing in research and development of effective therapeutics and vaccines to address emerging variants. Furthermore, it highlights the role of monoclonal antibodies as valuable tools in managing the ongoing pandemic.
Conclusion
Invivyd’s latest data on the in vitro neutralization activity of PEMGARDA and VYD2311 against the dominant SARS-CoV-2 variant, LP.8.1, is a promising development for immunocompromised individuals and the global community. The consistent neutralization activity of these mAbs against this variant reinforces their value as protective measures and potential future therapeutic options. As the fight against COVID-19 continues, it is crucial to stay informed about the latest developments and to prioritize vaccination and other preventative measures.
- Invivyd’s PEMGARDA (pemivibart) demonstrates consistent in vitro neutralization activity against the currently dominant SARS-CoV-2 variant, LP.8.1.
- The epitope targeted by PEMGARDA and next-generation mAb candidate VYD2311 remains structurally intact, ensuring their continued effectiveness.
- PEMGARDA is authorized in the U.S. for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients.
- The data is encouraging for individuals at higher risk of severe COVID-19 and underscores the importance of investing in research and development of effective therapeutics and vaccines.
